Thursday, 21 May 2020 16:31

Prati-Donaduzzi remains its international business strategies despite the change of scenario

Victor Donaduzzi_.jpg

Director Victor Donaduzzi will conduct the activities of the international business office. Photo: Prati-Donaduzzi. 

Prati-Donaduzzi, which is based in Toledo in the West of Paraná, remains with the international business strategy. The company has planned to expand the market for years, and it was looking for a big leap for 2020. The change in the global economic and health scenario did not prevent the work from continuing. The pharmaceutical industry is getting adapted to the moment, but it still aims to advance the frontiers.

The plan for a facility on U.S. soil was paused due to the pandemic. An international business office will be set up, for now, in Brazil, but with the same objective of prospecting products in the area of ​​the Central Nervous System (CNS) and setting up partnerships, searching for opportunities and raising innovations.

By heading the office, Victor Donaduzzi, the Associate Director, will conduct the activities remotely. The new challenge is aligned with the experience with cutting-edge technology and innovations that the director has developed by leading Centralpack, packaging company of Prati-Donaduzzi group, for over five years.

“It is a great satisfaction to carry out this work and be part of this new moment for the company. Prati-Donaduzzi has a history of assertive growth and needs to keep evolving, so we are constantly looking for 'new formulas'. Expansion of activities and prospecting for innovations and technology are examples”, says Victor.

Central Nervous System

Prati-Donaduzzi is currently certified by the National Sanitation Foundation (NSF) and exports a wide range of functional foods to the U.S. market. However, international prospects are gaining even more strength for the company because recently the industry received authorization from Brazilian Health Regulatory Agency (Anvisa) for the production of the first national Cannabidiol.

In addition to this product, the company will market more than 20 branded drugs, most of which are aimed at the Central Nervous System (CNS) and indicated to treat diseases such as Parkinson's, Alzheimer's, epilepsy, anxiety, depression, neuropathic pain, schizophrenia, autism, bipolarity , restless legs syndrome and Obsessive Compulsive Disorder.

One of the initial activities of Prati-Donaduzzi's international business office is to search for products and technologies that might expand this portfolio. “All actions are part of a well-planned strategic plan and the social commitment we have, which is to take care of people's health. We are looking for a role in the international pharmaceutical market and some references in Research, Development and Innovation. We are big and we will be even bigger”, emphasizes the director.


Read 968 times